Symbols / BNGO $1.15 +1.77%
BNGO Chart
About
Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It also provides Saphyr and Stratys systems, which are sample-to-result solutions for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr and Stratys instruments, which are single-molecule imagers; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA; and Ionic purification system, which isolates and purifies nucleic acid molecules. In addition, the company offers Saphyr, Stratys, and Bionano compute servers; and VIA software, which offers one solution for analysis and interpretation of genomic data from microarray and sequencing data for cytogenetics and molecular genetics. Further, it provides testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Medical Instruments & Su | Market Cap | 11.13M |
| Enterprise Value | 7.32M | Income | -38.59M | Sales | 28.72M |
| Book/sh | 5.12 | Cash/sh | 2.12 | Dividend Yield | — |
| Payout | 0.00% | Employees | 98 | IPO | — |
| P/E | — | Forward P/E | -0.46 | PEG | — |
| P/S | 0.39 | P/B | 0.22 | P/C | — |
| EV/EBITDA | -0.45 | EV/Sales | 0.26 | Quick Ratio | 1.14 |
| Current Ratio | 2.12 | Debt/Eq | 34.53 | LT Debt/Eq | — |
| EPS (ttm) | -12.77 | EPS next Y | -2.49 | EPS Growth | — |
| Revenue Growth | 21.30% | Earnings | 2026-03-23 | ROA | -19.31% |
| ROE | -78.22% | ROIC | — | Gross Margin | 45.97% |
| Oper. Margin | -115.89% | Profit Margin | -134.36% | Shs Outstand | 9.68M |
| Shs Float | 8.52M | Short Float | 11.78% | Short Ratio | 4.03 |
| Short Interest | — | 52W High | 5.50 | 52W Low | 1.06 |
| Beta | 1.72 | Avg Volume | 193.90K | Volume | 82.09K |
| Target Price | $5.50 | Recom | Strong_buy | Prev Close | $1.13 |
| Price | $1.15 | Change | 1.77% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$5.50
Mean price target
2. Current target
$1.15
Latest analyst target
3. DCF / Fair value
$5.25
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.15
Low
$4.00
High
$7.00
Mean
$5.50
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-11-24 | main | HC Wainwright & Co. | Buy → Buy | $7 |
| 2025-08-18 | main | HC Wainwright & Co. | Buy → Buy | $11 |
| 2025-05-20 | up | Maxim Group | Hold → Buy | $8 |
| 2025-04-09 | init | HC Wainwright & Co. | — → Buy | $10 |
| 2025-04-02 | main | Scotiabank | Sector Perform → Sector Perform | $4 |
| 2024-11-15 | down | Ladenburg Thalmann | Buy → Neutral | — |
| 2024-05-16 | main | BTIG | Buy → Buy | $2 |
| 2024-03-07 | main | Scotiabank | Sector Outperform → Sector Outperform | $6 |
| 2023-11-13 | down | Maxim Group | Buy → Hold | — |
| 2023-08-10 | main | BTIG | Buy → Buy | $10 |
- Bionano to Report Fourth Quarter and Full Year 2025 - GlobeNewswire Mon, 09 Mar 2026 20
- How Low Can Bionano Genomics Stock Really Go? - Trefis Sun, 21 Dec 2025 08
- Despite Fast-paced Momentum, Bionano Genomics (BNGO) Is Still a Bargain Stock - Yahoo Finance Mon, 08 Sep 2025 07
- How labs aim to map 10,000 genomes a year with cheaper OGM tech - Stock Titan Fri, 27 Feb 2026 08
- Market Cool On Bionano Genomics, Inc.'s (NASDAQ:BNGO) Revenues - simplywall.st Fri, 30 Jan 2026 08
- Bionano Genomics (BNGO) Is Attractively Priced Despite Fast-paced Momentum - Nasdaq Fri, 22 Aug 2025 07
- Bionano Genomics, Inc. Announces Pricing of $10 Million Public Offering of Common Stock and Warrants - Quiver Quantitative ue, 16 Sep 2025 07
- Maxim Group Maintains Bionano Genomics(BNGO.US) With Buy Rating, Cuts Target Price to $4 - 富途牛牛 Fri, 06 Mar 2026 14
- Inside the tech spotting hidden cancer DNA errors and testing gene therapies - Stock Titan Wed, 25 Feb 2026 08
- Earnings call transcript: Bionano Genomics Q2 2025 sees revenue drop, stock dips - Investing.com hu, 14 Aug 2025 07
- Bionano Genomics Second Quarter 2025 Earnings: Beats Expectations - simplywall.st Sat, 16 Aug 2025 07
- Scientists from 70 countries explore new DNA mapping tools for blood cancers - Stock Titan ue, 24 Feb 2026 08
- Bionano Genomics closes $10 million public offering - Investing.com Wed, 17 Sep 2025 07
- Bionano Genomics Inc (BNGO) Q1 2025 Earnings Call Highlights: Navigating Revenue Challenges ... - Yahoo Finance hu, 15 May 2025 07
- New genome mapping tech finds hidden genetic changes in autism, pregnancy loss - Stock Titan hu, 26 Feb 2026 08
Insider Transactions
| Date | Shares | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|
| 0 | 16000 | — | — | CHAUBEY ALKA PH.D. | Officer | — | 2024-06-03 00:00:00 | D |
| 1 | 14500 | — | — | DIXON JONATHAN V | General Counsel | — | 2024-06-03 00:00:00 | D |
| 2 | 16000 | — | — | KAMA GULSEN | Chief Financial Officer | — | 2024-06-03 00:00:00 | D |
| 3 | 44000 | — | — | HOLMLIN R ERIK | Chief Executive Officer | — | 2024-06-03 00:00:00 | D |
| 4 | 16000 | — | — | OLDAKOWSKI MARK | Chief Operating Officer | — | 2024-06-03 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -6.53M | -16.38M | 0.00 | -22.02K |
| TaxRateForCalcs | 0.21 | 0.21 | 0.21 | 0.07 |
| NormalizedEBITDA | -64.30M | -143.50M | -120.57M | -73.55M |
| TotalUnusualItems | -31.08M | -78.02M | 0.00 | -301.00K |
| TotalUnusualItemsExcludingGoodwill | -31.08M | -78.02M | 0.00 | -301.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -112.02M | -232.49M | -132.60M | -72.44M |
| ReconciledDepreciation | 14.23M | 13.91M | 9.84M | 3.37M |
| ReconciledCostOfRevenue | 30.40M | 26.55M | 21.86M | 14.11M |
| EBITDA | -95.39M | -221.52M | -120.57M | -73.86M |
| EBIT | -109.61M | -235.43M | -130.41M | -77.22M |
| NetInterestIncome | -3.91M | -17.04M | 1.21M | -691.00K |
| InterestExpense | 2.37M | -3.00M | 298.00K | 927.00K |
| InterestIncome | 2.10M | 3.31M | 1.51M | 236.00K |
| NormalizedIncome | -87.46M | -170.86M | -132.60M | -72.16M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -112.02M | -232.49M | -132.60M | -72.44M |
| TotalExpenses | 107.05M | 173.34M | 159.50M | 95.08M |
| TotalOperatingIncomeAsReported | -103.98M | -215.25M | -131.70M | -77.10M |
| DilutedAverageShares | 1.87M | 569.00K | 495.30K | 482.67K |
| BasicAverageShares | 1.87M | 569.00K | 495.30K | 482.67K |
| DilutedEPS | -60.05 | -408.60 | -267.71 | -150.07 |
| BasicEPS | -60.05 | -408.60 | -267.71 | -150.07 |
| DilutedNIAvailtoComStockholders | -112.02M | -232.49M | -132.60M | -72.44M |
| NetIncomeCommonStockholders | -112.02M | -232.49M | -132.60M | -72.44M |
| NetIncome | -112.02M | -232.49M | -132.60M | -72.44M |
| NetIncomeIncludingNoncontrollingInterests | -112.02M | -232.49M | -132.60M | -72.44M |
| NetIncomeContinuousOperations | -112.02M | -232.49M | -132.60M | -72.44M |
| TaxProvision | 33.00K | 62.00K | 1.88M | -5.72M |
| PretaxIncome | -111.98M | -232.43M | -130.71M | -78.15M |
| OtherIncomeExpense | -31.80M | -78.17M | -223.00K | -360.00K |
| OtherNonOperatingIncomeExpenses | -716.00K | -148.00K | -223.00K | -59.00K |
| SpecialIncomeCharges | -31.08M | -78.02M | 0.00 | -301.00K |
| OtherSpecialCharges | 3.38M | 301.00K | ||
| ImpairmentOfCapitalAssets | 19.68M | 77.28M | 0.00 | |
| RestructuringAndMergernAcquisition | 8.02M | 741.00K | ||
| NetNonOperatingInterestIncomeExpense | -3.91M | -17.04M | 1.21M | -691.00K |
| TotalOtherFinanceCost | 3.64M | 23.35M | ||
| InterestExpenseNonOperating | 2.37M | -3.00M | 298.00K | 927.00K |
| InterestIncomeNonOperating | 2.10M | 3.31M | 1.51M | 236.00K |
| OperatingIncome | -76.28M | -137.22M | -131.70M | -77.10M |
| OperatingExpense | 76.66M | 146.79M | 137.64M | 80.97M |
| ResearchAndDevelopment | 24.80M | 54.03M | 49.05M | 22.48M |
| SellingGeneralAndAdministration | 51.85M | 92.76M | 88.60M | 58.49M |
| GrossProfit | 380.00K | 9.57M | 5.95M | 3.87M |
| CostOfRevenue | 30.40M | 26.55M | 21.86M | 14.11M |
| TotalRevenue | 30.78M | 36.12M | 27.80M | 17.98M |
| OperatingRevenue | 30.78M | 36.12M | 27.80M | 17.98M |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 1.87M | 762.53K | 495.30K | 482.67K |
| ShareIssued | 1.87M | 762.53K | 495.30K | 482.67K |
| NetDebt | 51.85M | |||
| TotalDebt | 6.93M | 9.61M | 11.67M | 10.70M |
| TangibleBookValue | 25.67M | 62.19M | 130.97M | 254.12M |
| InvestedCapital | 35.38M | 96.16M | 249.40M | 337.12M |
| WorkingCapital | 2.15M | 40.09M | 121.41M | 250.57M |
| NetTangibleAssets | 25.67M | 62.19M | 130.97M | 254.12M |
| CapitalLeaseObligations | 6.93M | 9.61M | 11.67M | 10.70M |
| CommonStockEquity | 35.38M | 96.16M | 249.40M | 337.12M |
| TotalCapitalization | 35.38M | 96.16M | 249.40M | 337.12M |
| TotalEquityGrossMinorityInterest | 35.38M | 96.16M | 249.40M | 337.12M |
| StockholdersEquity | 35.38M | 96.16M | 249.40M | 337.12M |
| GainsLossesNotAffectingRetainedEarnings | 27.00K | 23.00K | -1.12M | -539.00K |
| OtherEquityAdjustments | 27.00K | 23.00K | -1.12M | -539.00K |
| RetainedEarnings | -693.23M | -581.21M | -348.71M | -216.12M |
| AdditionalPaidInCapital | 728.57M | 677.34M | 599.23M | 553.75M |
| CapitalStock | 0.00 | 0.00 | 3.00K | 29.00K |
| CommonStock | 0.00 | 0.00 | 3.00K | 29.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 41.30M | 118.25M | 58.10M | 39.98M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 3.95M | 18.22M | 22.22M | 18.14M |
| OtherNonCurrentLiabilities | 10.89M | 12.97M | 9.07M | |
| NonCurrentDeferredLiabilities | 267.00K | 154.00K | 127.00K | 146.00K |
| NonCurrentDeferredRevenue | 267.00K | 154.00K | 127.00K | 146.00K |
| LongTermDebtAndCapitalLeaseObligation | 3.68M | 7.17M | 9.12M | 8.93M |
| LongTermCapitalLeaseObligation | 3.68M | 7.17M | 9.12M | 8.93M |
| CurrentLiabilities | 37.34M | 100.03M | 35.88M | 21.84M |
| OtherCurrentLiabilities | 20.36M | 78.34M | 9.38M | 175.00K |
| CurrentDeferredLiabilities | 1.15M | 800.00K | 888.00K | 1.51M |
| CurrentDeferredRevenue | 1.15M | 800.00K | 888.00K | 1.51M |
| CurrentDebtAndCapitalLeaseObligation | 3.25M | 2.44M | 2.54M | 1.77M |
| CurrentCapitalLeaseObligation | 3.25M | 2.44M | 2.54M | 1.77M |
| CurrentDebt | 69.80M | |||
| OtherCurrentBorrowings | 69.80M | |||
| PensionandOtherPostRetirementBenefitPlansCurrent | 1.98M | 5.03M | 7.00M | 4.53M |
| CurrentProvisions | 276.00K | 391.00K | ||
| PayablesAndAccruedExpenses | 10.33M | 13.04M | 16.07M | 14.04M |
| CurrentAccruedExpenses | 2.64M | 1.55M | 2.71M | 2.59M |
| InterestPayable | 0.00 | |||
| Payables | 7.69M | 11.48M | 13.36M | 11.45M |
| TotalTaxPayable | 729.00K | 1.10M | 825.00K | 677.00K |
| AccountsPayable | 6.96M | 10.38M | 12.53M | 10.77M |
| TotalAssets | 76.67M | 214.40M | 307.50M | 377.10M |
| TotalNonCurrentAssets | 37.18M | 74.28M | 150.20M | 104.69M |
| OtherNonCurrentAssets | 3.15M | 7.83M | 2.81M | 749.00K |
| GoodwillAndOtherIntangibleAssets | 9.70M | 33.97M | 118.43M | 83.00M |
| OtherIntangibleAssets | 9.70M | 33.97M | 41.14M | 26.84M |
| Goodwill | 0.00 | 77.29M | 56.16M | |
| NetPPE | 24.32M | 32.48M | 28.96M | 20.93M |
| AccumulatedDepreciation | -26.86M | -19.08M | -13.08M | -9.07M |
| GrossPPE | 51.18M | 51.56M | 42.03M | 30.01M |
| Leases | 3.33M | 3.75M | 4.00M | 2.67M |
| OtherProperties | 45.14M | 44.83M | 36.41M | 26.51M |
| MachineryFurnitureEquipment | 2.72M | 2.98M | 1.62M | 819.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 39.49M | 140.12M | 157.30M | 272.41M |
| OtherCurrentAssets | 1.32M | 976.00K | 2.41M | 1.38M |
| RestrictedCash | 11.00M | 35.12M | ||
| PrepaidAssets | 1.80M | 4.70M | 4.44M | 2.72M |
| Inventory | 11.12M | 22.89M | 29.76M | 12.39M |
| FinishedGoods | 17.39M | 6.08M | ||
| WorkInProcess | 7.05M | 1.66M | ||
| RawMaterials | 5.32M | 4.65M | ||
| Receivables | 4.77M | 9.66M | 7.50M | 5.32M |
| AccruedInterestReceivable | 22.00K | 342.00K | 474.00K | 387.00K |
| AccountsReceivable | 4.75M | 9.32M | 7.02M | 4.93M |
| AllowanceForDoubtfulAccountsReceivable | -157.00K | -483.00K | -293.00K | -690.00K |
| GrossAccountsReceivable | 4.91M | 9.80M | 7.32M | 5.62M |
| CashCashEquivalentsAndShortTermInvestments | 9.47M | 66.77M | 113.19M | 250.61M |
| OtherShortTermInvestments | 302.00K | 48.82M | 108.09M | 226.04M |
| CashAndCashEquivalents | 9.17M | 17.95M | 5.09M | 24.57M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -69.03M | -126.87M | -128.12M | -73.39M |
| RepaymentOfDebt | -66.06M | -9.05M | -36.00K | -15.01M |
| IssuanceOfDebt | 18.00M | 80.00M | 0.00 | 0.00 |
| IssuanceOfCapitalStock | 44.43M | 57.70M | 23.13M | 342.71M |
| CapitalExpenditure | -103.00K | -1.69M | -3.30M | -1.46M |
| InterestPaidSupplementalData | 10.65M | 1.65M | 298.00K | 1.91M |
| EndCashPosition | 9.57M | 18.35M | 5.49M | 24.57M |
| BeginningCashPosition | 18.35M | 5.49M | 24.57M | 38.45M |
| EffectOfExchangeRateChanges | -7.00K | 65.00K | -38.00K | 0.00 |
| ChangesInCash | -8.77M | 12.79M | -19.04M | -13.88M |
| FinancingCashFlow | -13.69M | 113.81M | 23.01M | 336.11M |
| CashFlowFromContinuingFinancingActivities | -13.69M | 113.81M | 23.01M | 336.11M |
| NetOtherFinancingCharges | -10.07M | -14.96M | -578.00K | -1.70M |
| ProceedsFromStockOptionExercised | 15.00K | 130.00K | 493.00K | 10.11M |
| NetCommonStockIssuance | 44.43M | 57.70M | 23.13M | 342.71M |
| CommonStockIssuance | 44.43M | 57.70M | 23.13M | 342.71M |
| NetIssuancePaymentsOfDebt | -48.06M | 70.95M | -36.00K | -15.01M |
| NetShortTermDebtIssuance | 0.00 | |||
| ShortTermDebtPayments | 0.00 | |||
| ShortTermDebtIssuance | 0.00 | |||
| NetLongTermDebtIssuance | -48.06M | 70.95M | -36.00K | -15.01M |
| LongTermDebtPayments | -66.06M | -9.05M | -36.00K | -15.01M |
| LongTermDebtIssuance | 18.00M | 80.00M | 0.00 | 0.00 |
| InvestingCashFlow | 73.84M | 24.16M | 82.77M | -278.06M |
| CashFlowFromContinuingInvestingActivities | 73.84M | 24.16M | 82.77M | -278.06M |
| NetOtherInvestingChanges | 694.00K | -607.00K | ||
| NetInvestmentPurchaseAndSale | 73.94M | 25.75M | 116.69M | -226.91M |
| SaleOfInvestment | 306.96M | 137.02M | 200.89M | 86.48M |
| PurchaseOfInvestment | -233.02M | -111.26M | -84.19M | -313.39M |
| NetBusinessPurchaseAndSale | 0.00 | 96.00K | -31.34M | -49.09M |
| SaleOfBusiness | 0.00 | 96.00K | 0.00 | |
| PurchaseOfBusiness | 0.00 | -31.34M | -49.09M | |
| NetIntangiblesPurchaseAndSale | 0.00 | -102.00K | 0.00 | |
| PurchaseOfIntangibles | 0.00 | -102.00K | 0.00 | |
| NetPPEPurchaseAndSale | -103.00K | -1.69M | -3.17M | -1.46M |
| SaleOfPPE | 0.00 | 26.00K | 0.00 | |
| PurchaseOfPPE | -103.00K | -1.69M | -3.20M | -1.46M |
| OperatingCashFlow | -68.92M | -125.18M | -124.82M | -71.93M |
| CashFlowFromContinuingOperatingActivities | -68.92M | -125.18M | -124.82M | -71.93M |
| InterestPaidCFO | 0.00 | -1.24M | ||
| ChangeInWorkingCapital | 4.40M | -14.77M | -27.94M | -7.65M |
| ChangeInOtherCurrentAssets | 4.68M | -5.02M | -1.13M | -647.00K |
| ChangeInPayablesAndAccruedExpense | -5.41M | -4.52M | 2.31M | 10.74M |
| ChangeInAccruedExpense | -1.99M | -2.52M | 366.00K | 3.96M |
| ChangeInPayable | -3.42M | -2.00M | 1.95M | 6.78M |
| ChangeInAccountPayable | -3.42M | -2.00M | 1.95M | 6.78M |
| ChangeInPrepaidAssets | 1.58M | 1.21M | -3.20M | -1.32M |
| ChangeInInventory | -587.00K | -4.15M | -23.68M | -15.93M |
| ChangeInReceivables | 4.14M | -2.30M | -2.25M | -493.00K |
| ChangesInAccountReceivables | 4.14M | -2.30M | -2.25M | -493.00K |
| OtherNonCashItems | -9.20M | 16.42M | 794.00K | 1.48M |
| StockBasedCompensation | 9.74M | 15.18M | 22.42M | 9.72M |
| UnrealizedGainLossOnInvestmentSecurities | -8.12M | -575.00K | ||
| ProvisionandWriteOffofAssets | 649.00K | 0.00 | ||
| AssetImpairmentCharge | 26.91M | 77.28M | 0.00 | 0.00 |
| AmortizationOfSecurities | -1.32M | -539.00K | 638.00K | 329.00K |
| DeferredTax | 0.00 | 1.76M | -5.78M | |
| DeferredIncomeTax | 0.00 | 1.76M | -5.78M | |
| DepreciationAmortizationDepletion | 14.23M | 13.91M | 9.84M | 3.37M |
| DepreciationAndAmortization | 14.23M | 13.91M | 9.84M | 3.37M |
| Depreciation | 14.23M | 13.91M | 9.84M | 3.37M |
| OperatingGainsLosses | 6.45M | 405.00K | 270.00K | 273.00K |
| GainLossOnInvestmentSecurities | 14.00K | 23.00K | 66.00K | |
| GainLossOnSaleOfPPE | 3.06M | 382.00K | 204.00K | 568.00K |
| NetIncomeFromContinuingOperations | -112.02M | -232.49M | -132.60M | -72.44M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for BNGO
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|